In this article, Dr. Vrijens shares his thoughts on the need for dose optimization in the interests of balancing safety and efficacy. How we use language has a huge bearing on the meaning we convey. Take the word ‘overdose’, for … Read More
Author Archives: Bernard Vrijens
From Estimation to Calculation: Exploring the Power of Medication Adherence Data
In this article, Dr. Bernard Vrijens discusses the importance of medication adherence data in clinical trials and why medication adherence should be a calculation, not an estimation. The world is today collecting a mind-blowing amount of data. Indeed, IDC calculates that about … Read More
ROI: Understanding the True Cost of Medication Non-Adherence in Clinical Trials
In this article, our Scientific Lead, Bernard Vrijens, discusses the influence of medication non-adherence on ROI in clinical trials. Get ready for an insightful read! Fraught with risk yet pivotal to the future success of a drug candidate, clinical trials … Read More
FDA Proposes Updates to Drug Labeling Regs to Include New Patient Medication Information (PMI) Guide for Prescription Drug Products
This action, if finalized, will require applicants to create a new type of medication guide, referred to as Patient Medication Information (PMI). In this article, our Scientific Lead, Bernard Vrijens, unpacks the proposals and questions whether more is needed to … Read More
AARDEX Group Announced as Founding Member of CancerX Initiative to Drive Innovation in the Fight Against Cancer
Adherence specialists join multi-stakeholder CancerX initiative to improve long-term pathways for cancer patients and meet the challenge of oral treatments. Liege, Belgium- July 18, 2023: Adherence specialist AARDEX Group is proud to announce it is a founding member of the CancerX initiative, bringing … Read More
Tackling Toxicity in the Era of Oral Chemotherapy Drugs
In recent decades we have witnessed a shift in how chemotherapy drugs are administered. Historically, cytotoxic chemotherapies were almost exclusively administered by a healthcare professional (HCP) via injection or intravenous drip, but today, oral chemotherapy drug forms are becoming increasingly … Read More
AARDEX Group Partners with Mevia
Integration of AARDEX MEMS AS and MEMS Mobile technology with Mevia’s Medose dispenser offers opportunity to pilot next stage in reusable and real-time adherence solutions. Liege, Belgium- June 8th, 2023: Adherence specialist AARDEX Group is proud to announce its partnership with Mevia, a … Read More
AARDEX Group Partners with Industry Leaders on DiMe’s Digital Medicine Society’s V3+ Framework Project to Enhance Usability of DHTs
Extending the Verification, Analytical Validation and Clinical Validation (V3+) Framework Project will ensure digital clinical measures and products meet the needs of larger audiences. Liege, Belgium- May 3, 2023: Adherence specialists AARDEX Group is proud to announce its partnership with other industry leaders … Read More
Meet us at Outsourcing in Clinical Trials Europe 2023
Exciting news! AARDEX Group is gearing up for one of the most highly anticipated events in the clinical trials industry – the 13th Annual Outsourcing in Clinical Trials Europe conference, which will take place in the beautiful city of Barcelona … Read More
Pill Count Compliance: It’s Time to Burst the Drug Trial Bubble
In this article, our Scientific Lead and Adherence Expert, Bernard Vrijens, explores the use of pill count compliance in clinical trials and its reliability for measuring medication adherence. Pressure is ubiquitous when it comes to conducting clinical trials. Sponsors feel the … Read More